ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KLRS
LONA (35) IMA (19) TIL (39) CRBU (32) ⌘ Pro Terminal →

Kalaris Therapeutics Inc. (KLRS) — RQD Stock Rating Cockpit

$2.00 -1.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.99

Kalaris Therapeutics Inc. (KLRS) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $48.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KLRS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KLRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kalaris Therapeutics Inc. (NASDAQ: KLRS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.00 (-1.48% 1D, market cap $48.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KLRS compare to LONA and IMA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KLRS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M) and IMA (ImageneBio Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M). Among the 5-stock peer group, KLRS leads on earnings multiple (N/A) while KLRS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KLRS?
▼

Per KLRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754068), Kalaris Therapeutics Inc. generated $129.2M in revenue (-10.8% YoY), -$43.4M in net income, and -$38.6M in free cash flow against $121.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.99 (-0.46%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (4)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$12 Bull$2 Base$1 Bear
📬 FREE KLRS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KLRS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY KLRS SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$2.23-7.2% Next Q
Q2 (-2Q)
35
Grade E$2.07-10.1% Next Q
Q3 (-1Q)
33
Grade E$1.86+7.5% Next Q
Current
30
Grade E$2.00-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KLRS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KLRS currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.87) and Max Pain ($2.10) forces dealer call-delta covering toward $12.47.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KLRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KLRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
38.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$2.00H: $12
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on KLRS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like KLRS
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KLRS)

  • ✓Walkthrough of KLRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KLRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.83%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.13H $2.13L $2.00C $2.00VOL 60.2K
RES: $7.62SUP: $1.68SMA50: $2.87SMA200: $5.33
$7.74$6.12$4.51$2.89$1.28RES $7.62SUP $1.68$2.002026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KLRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KLRS Butterfly Map → + Track KLRS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -10.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KLRS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KLRS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KLRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KLRS)

Health Care Rank #805 of 1015 ⚔️ LONA vs KLRS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KLRS vs. LONA, IMA, TIL, CRBU)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kalaris Therapeutics Inc. (KLRS) ranks #805 by composite RQD confidence (30/100, grade E) and #750 by equity capitalization ($48.3M). Within this direct 5-issuer industry benchmark cohort, KLRS leads on earnings valuation at N/A trailing P/E, while KLRS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with KLRS at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KLRS ACTIVE
Kalaris Therapeutics Inc.
E 30/100 — — -35.0% -1.48% $48.3M Benchmark Subject
LONA
LeonaBio Inc.
D- 35/100 — — -35.0% -4.25% $46.5M /lona-vs-klrs →
IMA
ImageneBio Inc.
E 19/100 — — -35.0% -0.24% $46.5M /ima-vs-klrs →
TIL
Instil Bio Inc.
D- 39/100 — — -35.0% -3.68% $46.1M /til-vs-klrs →
CRBU
Caribou Biosciences Inc.
E 32/100 — — -35.0% +3.95% $45.4M /crbu-vs-klrs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001754068 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kalaris Therapeutics Inc. (KLRS) reported GAAP revenue of $129.2M (-10.8% vs. FY2024 revenue of $144.8M , and -76.9% cumulative change since FY2023) , GAAP net income of -$43.4M, operating cash flow of -$38.4M, and free cash flow of -$38.6M (-86.6% YoY). On the balance sheet, KLRS closed FY2025 with $121.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $129.2M -$43.4M -$38.4M -$38.6M $121.7M —
FY2024 (FY) 2024-12-31 $144.8M -$69.2M -$20.7M -$20.7M $6.2M —
FY2023 (FY) 2023-12-31 $559.7M -$190.4M -$124.5M -$124.5M — —

3. KLRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KLRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kalaris Therapeutics Inc. (NASDAQ: KLRS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.00 (-1.48% 1D, market cap $48.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does KLRS compare to LONA and IMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KLRS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M) and IMA (ImageneBio Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M). Among the 5-stock peer group, KLRS leads on earnings multiple (N/A) while KLRS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KLRS?

Per KLRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754068), Kalaris Therapeutics Inc. generated $129.2M in revenue (-10.8% YoY), -$43.4M in net income, and -$38.6M in free cash flow against $121.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KLRS trading relative to its 50-day, 200-day, and 52-week technical levels?

KLRS last traded at $2.00 (-1.48% on volume of 59,274 shares), positioning the stock -30.31% below its 50-day simple moving average ($2.87) and -62.48% below its 200-day simple moving average ($5.33). Across its 52-week range of $1.78 to $11.88, KLRS sits at the 2.2% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.75 to $2.25).

Direct Sub-Reports: KLRS RQD Cockpit KLRS 12M Forecast KLRS Earnings & Move KLRS Dividends & DRIP KLRS Insiders & 13F KLRS Whale Options KLRS Profit Sankey KLRS News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

KLRS — Kalaris Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kalaris Therapeutics Inc. (KLRS) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.00 (-1.48% 1D, market capitalization $48.3M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (KLRS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Reported revenue is — in each of the FY 2023, FY 2024, and FY 2025 periods, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kalaris Therapeutics Inc. (KLRS) reported $129.2M in annual revenue (up from $144.8M in FY2024, -10.8% YoY) and -$43.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($559.7M revenue, -$190.4M net income) through FY2025, KLRS scaled operating cash flow to -$38.4M and free cash flow to -$38.6M, backed by $121.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.78 – $11.88 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level linkage in the source is the liquidity signal, which assigns KLRS a 2.86x sensitivity to Net Liquidity changes. Investors should watch for a reversal in the liquidity backdrop, since the signal's bullish reading depends on current Fed, Treasury General Account, and Reverse Repo levels. The sensitivity is high but the correlation is weak at r = -0.18, so the signal explains only a limited share of return variation.

  • Key Question #1: Can KLRS sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $129.2M and free cash flow of -$38.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KLRS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KLRS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kalaris Therapeutics Inc. (KLRS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KLRS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KLRS Bull vs. Bear Conversation Board — What's Your Call at $2.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KLRS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KLRS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.40 (+18.2%)
📌 Pinned Debate

The liquidity signal rates KLRS at a 2.86x Net Liquidity sensitivity with a macro tailwind score of 91/100 under current Fed plumbing.

Here is why I am bullish on KLRS here at $2.03: The liquidity signal rates KLRS at a 2.86x Net Liquidity sensitivity with a macro tailwind score of 91/100 under current Fed plumbing.. Compare KLRS's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $1.93 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — KLRS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.66 (-18.2%)
Spot @ $2.03

KLRS reports zero revenue and operating losses across FY 2023–2025 with an RQD cash-engine pillar of 4/20 and ROIC of -35%.

Sitting on the sidelines or leaning short KLRS above $2.03. KLRS reports zero revenue and operating losses across FY 2023–2025 with an RQD cash-engine pillar of 4/20 and ROIC of -35%.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $11.88.

LIVE TAPE